| Hubert Fornalik, MD | |
|
5340 Holy Cross Pkwy, Mishawaka, IN 46545-1470 | |
| (574) 237-1328 | |
| Not Available |
| Full Name | Hubert Fornalik |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 24 Years |
| Location | 5340 Holy Cross Pkwy, Mishawaka, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255549812 | NPI | - | NPPES |
| 200978000 | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospital | Munster, IN | Hospital |
| Lutheran Hospital Of Indiana | Fort wayne, IN | Hospital |
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Care Network Inc | 3678737012 | 360 |
| Lutheran Medical Group Llc | 4981751617 | 261 |
| Northwest Cancer Centers, P.c. | 4587553474 | 24 |
| The Methodist Hospitals Inc | 9638063894 | 89 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
| Entity Name | The Methodist Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124283858 PECOS PAC ID: 9638063894 Enrollment ID: O20040303000549 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
| Entity Name | Northwest Cancer Centers, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578527826 PECOS PAC ID: 4587553474 Enrollment ID: O20040310001213 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
| Entity Name | Lutheran Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164662805 PECOS PAC ID: 4981751617 Enrollment ID: O20090414000705 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
| Entity Name | Community Care Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457610487 PECOS PAC ID: 3678737012 Enrollment ID: O20120614000331 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hubert Fornalik, MD 100 E Wayne St Ste 510, South Bend, IN 46601-2394 Ph: (574) 334-5400 | Hubert Fornalik, MD 5340 Holy Cross Pkwy, Mishawaka, IN 46545-1470 Ph: (574) 237-1328 |
News Archive
Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.
The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.
Alzheimer's, Parkinson's and Huntington's disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three.
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.
› Verified 5 days ago
Asad U. Sheikh, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd, Suite 408, Mishawaka, IN 46545 Phone: 574-335-6440 Fax: 574-335-0608 | |
Dr. Jodi Carbone, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 212 W Edison Rd, Suite F, Mishawaka, IN 46545 Phone: 574-257-0621 Fax: 574-257-0641 | |
Katherine Oleary, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 611 E Douglas Rd Ste 408, Mishawaka, IN 46545 Phone: 574-335-6440 Fax: 574-335-0806 | |
David William Parker, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd, Suite 408, Mishawaka, IN 46545 Phone: 574-335-6440 Fax: 574-333-5060 | |
Dr. Neil James Sink, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd Ste 408, Mishawaka, IN 46545 Phone: 574-335-6440 Fax: 574-335-0806 |